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Abbreviations 
AGA: Appropriate for Gestational Age 
BMI: Body Mass Index 
CI: Confidence Interval 
FGR: Fetal Growth Restriction 
GDM: Gestational Diabetes Mellitus 
HELLP: Hemolysis, Elevated Liver enzymes and Low Platelet count 
H.pylori: Helicobacter pylori 
LGA: Large for Gestational Age 
OR: Odds Ratio 
PE: Pre-eclampsia 
PIH: Pregnancy-Induced Hypertension 
pPROM: preterm Premature Rupture Of Membranes 
SGA: Small for Gestational Age 
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ABSTRACT 
The relationship between Helicobacter pylori infection and extragastric disease is well established. This study 
prospectively investigated whether maternal H. pylori seropositivity, detected during the first half of pregnancy, could 
be associated with the development of the major pregnancy-related pathologies during late second or third trimester in a 
general population. Our hypothesis was that H.pylori infection could negatively influence pregnancy development and 
outcome. A total of 2,820 consecutive pregnant women were recruited before 20 weeks of gestation, from October 2008 
to August 2010, and blood samples were collected from each subject. IgG antibodies against H.pylori were assayed in 
maternal serum by a commercial immunoassay. Logistic regression analyses were performed to assess any association 
between H.pylori seropositivity and adverse pregnancy outcomes. Gestational diabetes mellitus (GDM) was the most 
common maternal complication (5.7%) and the only pregnancy-related disorder with a significantly higher rate of 
H.pylori positive women (41.3%) compared to subjects who did not develop the disease (27.7%) (P < 0.001; OR = 
1.829, 95% CI = 1.320 – 2.533). The difference observed remained statistically significant after adjusting for potential 
confounding variables. The presence of antibodies against H.pylori antigens in maternal serum was independently 
associated with the development of GDM. These findings suggest a potential role for H.pylori eradication in the 
prevention of gestational diabetes mellitus. 
 
Key words: Helicobacter pylori; infection; pregnancy outcome; gestational diabetes mellitus. 
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1. Introduction 
Pre-eclampsia (PE), fetal growth restriction (FGR), preterm premature rupture of membranes (pPROM) and 
gestational diabetes mellitus (GDM) are serious pregnancy-related disorders having adverse effects on both maternal 
and fetal safety. A reduction in maternal mortality attributable to unfavorable pregnancy outcome has been observed in 
developed countries. However, perinatal mortality, perinatal and long term morbidity as well as neurological sequelae 
due to abnormal fetal growth and/or preterm delivery, remain high. Timely, and often preterm, delivery is the only 
current effective treatment. Nowadays there are only few options open to prevent these disorders, partly due to the fact 
that the etiology and the pathogenesis of pregnancy-related disorders are still poorly understood. We are of the opinion 
that infection alone, or as a cofactor in women with genetic susceptibility to adverse pregnancy outcome, might well 
play a role in the etiology and pathogenesis of pregnancy complications. 
Helicobacter pylori (H.pylori) infection affects approximately one half of the world’s population and is 
commonly associated with chronic gastritis, which increases the risk of many serious gastrointestinal complications, 
such as peptic ulcer disease and gastric cancer (Malaty, 2007). This is supported by several reports that indicate a 
correlation between H.pylori infection and various extra-gastric disorders (Banić et al., 2012), including some serious 
pregnancy-related pathologies, such as pre-eclampsia and/or fetal growth restriction (Cardaropoli et al., 2014). These 
pregnancy disorders, as well as numerous cases of miscarriage, mainly involve abnormal placentation. Indeed, it has 
recently demonstrated that antibodies against the H.pylori virulence factor CagA cross react in vitro with 
cytotrophoblast cells, reducing their invasive ability (Franceschi et al., 2012). 
Most publications on the correlation between H.pylori infection and pregnancy-related disorders are cross-
sectional investigations. The only prospective study on H pylori infection and pregnancy-related complications reported 
an association between maternal infections caused by H pylori CagA-strains and early pregnancy loss in patients given 
intra-cytoplasmic sperm injection (Hajishafiha et al., 2011). 
This study reports a prospective investigation into whether maternal H.pylori seropositivity, detected during 
the first half of pregnancy, could be associated with the development of the major pregnancy-related pathologies during 
late second or third trimester, in a general population. 
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2. Materials and methods 
2.1. SUBJECTS and DATA COLLECTION 
The study population included all consecutive pregnant women who had routine blood tests at the Laboratory of 
O.I.R.M. - Sant’Anna Hospital of Turin, between October 2008 and August 2010, before 20 weeks of gestational age. 
Any multiple pregnancies were excluded. This prospective cohort study was supported by The Italian Ministry of 
Health (No. RFPS-2007-4-638281), approved by our Hospital Ethics Committee and written informed consent was 
obtained from each subject enrolled. Blood samples were collected at recruitment and individual patient data included 
maternal demographic characteristics, previous obstetric and medical history, gestational age at recruitment, pre-
pregnancy weight and height for body mass index (BMI = Kg/m2) calculation, parity and smoking habit during 
pregnancy. 
Follow-up data were collected from the patients’ medical records or obtained by a postnatal interview one month after 
delivery i.e. gestational age and gestational weight gain at delivery, blood pressure measurements, urinary protein 
levels, any complications during pregnancy, mode of delivery, neonatal sex and birth weight (neonatal weight was also 
expressed as centiles, according to birth-weight references for the Italian population) (Bertino et al., 2010). 
2.2. DEFINITIONS 
Miscarriage included spontaneous miscarriage and/or fetal death before 23 weeks. Pre-eclampsia (PE) was defined as 
the onset of hypertension (systolic blood pressure >=140 mmHg or diastolic blood pressure >=90 mmHg) and 
proteinuria (>=300 mg/24h) after 20 weeks of gestational age in previously normotensive women, or a “new-onset 
proteinuria” in a woman with hypertension before 20 weeks of gestation, a sudden increase in proteinuria if it were 
already present in early gestation, or the development of HELLP syndrome (ACOG practice bulletin, 2002). PE was 
considered severe when one or more of the following criteria were present: systolic pressure >=160 mmHg or diastolic 
pressure >=110 mmHg on two occasions at least 6 hrs. apart, or significant proteinuria (>=3+ on urine dipstick or >5 g 
in a 24-hour urine), oliguria of  <500 mL in 24 hours, cerebral or visual disturbances, pulmonary edema or cyanosis, 
epigastric or right upper-quadrant pain, impaired liver function or thrombocytopenia (ACOG practice bulletin, 2002). 
Patients with PE were further classified as either having early-onset (<34 weeks), or late-onset (>=34 weeks), disease 
according to the gestational age when PE was diagnosed. The HELLP syndrome was defined by the following criteria: 
hemolysis (characteristic peripheral blood smear and serum lactate dehydrogenase ≥600 U/L), elevated liver enzymes 
(serum aspartate aminotransferase ≥70 U/L) and low platelet count (<100,000/µL) (Audibert et al., 1996). Pregnancy-
induced hypertension (PIH) was diagnosed when hypertension appeared after 20 weeks of gestational age in the 
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absence of significant proteinuria. Gestational diabetes mellitus (GDM) was defined as glucose intolerance with onset 
or first recognition during pregnancy. The diagnosis of GDM was based on the result of the 100g, 3 hour oral glucose 
tolerance test (2011). Obstetric cholestasis was diagnosed on the basis of the information obtained by clinical 
examination (generalized pruritus in the absence of any dermatologic condition), laboratory testing that showed a 
cholestatic pattern (abnormal liver function tests and serum total bile acids exceeding 10 µmol/L) that returned to 
normal values after delivery (Gynaecologists, 2011). Spontaneous preterm deliveries included those with spontaneous 
onset of labour and those with preterm pre-labour rupture of membranes before 37 weeks of gestation. 
The term Appropriate for gestational age (AGA) refers to neonates with a birth-weight between the 10th and the 90th 
centile according to birth-weight references for the Italian population (Bertino et al., 2010). SGA (Small for gestational 
age) was defined as newborns with a birth-weight between the 5th and the 9th centile. The classification FGR (Fetal 
growth restriction) was used for any pregnancies with very low birth-weight babies (birth-weight below the 5th centile) 
and/or SGA newborns with abnormal umbilical arteries Doppler flow velocity waveforms (FVWs) (Todros et al., 1996) 
and/or abnormal uterine artery Doppler FVWs (resistance index of >0.58) (Steel et al., 1990), when reported. Large for 
gestational age (LGA) neonates was used to define newborns with a birth-weight above the 90th centile, according to 
birth-weight references for the Italian population (Bertino et al., 2010). Gestational age was calculated from the first day 
of the last menstrual period and confirmed by ultrasound examination before 20 weeks of gestational age. 
2.3. SAMPLES 
Maternal blood samples (5 ml) were collected before 20 weeks of gestational age. Venous blood samples were collected 
in Vacutainer tubes (Becton Dickinson, Plymouth, UK) without anticoagulant and the serum was separated by 
centrifugation immediately after clotting and stored at -20°C until assayed. 
2.4. SEROLOGIC TESTS 
Both the presence and titer of antibodies (IgG) against Helicobacter pylori were determined in each serum sample using 
the qualitative/quantitative enzyme-linked immunosorbent assay BEIA Helicobacter pylori IgG Quant kit 
(Technogenetics Srl - Bouty Group, Sesto S.Giovanni, Milan, Italy) and an automatic analyzer, DSX® (DYNEX 
Technologies, Inc., Chantilly, VA). The concentration of IgG antibodies was calculated by a calibration curve expressed 
in Arbitrary Units/mL (AU/mL). The samples were considered positive for the presence of anti-Helicobacter pylori IgG 
antibodies when results showed > 11.5 AU/mL, as suggested by the test manufacturer. The sensitivity and specificity of 
the test were 96.25% and 99.1%, respectively, and the intra- and inter-assay coefficients of variation were lower than 
10%, as reported by the test manufacturer. 
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2.5. STATISTICAL ANALYSIS 
All data analyses were performed using the SPSS version 21.0 (SPSS Inc., Chicago, Illinois, USA). Continuous 
variables were reported as means and standard deviation (SD). The mean values between the two groups were analysed 
by the Student’s t-test, after evaluation of variance homogeneity using the Levene’s test. Categorical variables were 
presented as frequencies (percentages) and the different groups were compared by the chi-square test (χ2) by means of 
a 2x2 contingency table; Fisher’s exact test was used for small sample sizes. 
The odds ratios (OR) and 95% confidence intervals (CI), were calculated by a univariable logistic regression analysis to 
assess the risk of each pregnancy-related pathology associated with the positive test. Multivariable logistic regression 
analysis was performed to determine any association between H.pylori seropositivity and each of the adverse pregnancy 
outcomes, adjusted for maternal age, pre-pregnancy BMI, continent origin, smoking habit and the presence of maternal 
risk factors. All tests were two-tailed and the results were considered significant if they had a P value of less than 0.05. 
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3. RESULTS 
A total of 3,113 pregnant women were interviewed during the study period and 293 (9.4%) were excluded. These 
included 67 twin pregnancies, 25 pregnancies terminated either on psychosocial grounds or for structural and/or 
chromosomal malformations, 178 were lost at follow-up and 23 had been erroneously recruited twice. After exclusions, 
the study population was made up of 2,820 women recruited. Table 1 summarizes the main characteristics of our 
population at recruitment and delivery where serologic tests revealed that 804 (28.5%) women included in this study 
were seropositive for H.pylori. 
Gestational diabetes mellitus (GDM) was the most common maternal complication during pregnancy (n = 160, 5.7%) in 
our study population and was the only one with a statistically significantly higher percentage of H.pylori positive 
pregnant women i.e. (41.3%) compared to women without GDM (27.7%) (P < 0.001; OR = 1.829, 95% CI: 1.320 - 
2.533) (Table 2). When GDM alone without any other maternal pregnancy complication (GDM only group) was 
considered, the significant difference remained (Table 3). After adjustment for confounding factors the difference 
remained significant both for all GDM cases (P = 0.010) and the GDM only group (P = 0.009) (Table 4). A significant 
association between GDM development and maternal age, pre-pregnancy BMI, continent origin, a family history of 
diabetes and previous pregnancies complicated by GDM was demonstrated by multivariable logistic regression (Table 
4). The comparison between H.pylori seronegative and seropositive GDM indicated that seropositive mothers who 
subsequently developed gestational diabetes (seropositive GDM) were younger (33.2 years) and had a higher pre-
pregnancy BMI (26.4) than did seronegative GDM women (35.0 years and pre-pregnancy BMI of 23.9) (P = 0.013 and 
P = 0.004, respectively) (Supplementary Table 1). 
The percentage of H.pylori seropositive women with other maternal complications i.e. spontaneous preterm delivery, 
pregnancy-induced hypertension, pre-eclampsia, miscarriage or obstetric cholestasis, did not significantly differ from 
the percentage of H.pylori seropositive cases observed in women without these disorders during pregnancy (Tables 2-
3). When fetal growth was taken into consideration, the percentage of seropositive women with a SGA newborn was 
significantly lower (20.3%) than the rest of the study population (28.9%) (P = 0.033; OR = 0.626, 95% CI: 0.407 - 
0.963) (Table 2). The significant difference remained, when SGA was considered alone without any other pregnancy 
complication (P = 0.040) (Table 3), whilst FGR cases showed no differences for maternal H.pylori seropositivity (Table 
2-3). Conversely, the significant difference between LGA pregnancies (35.1%) and the other cases (27.9%) (P = 0.022) 
(Table 2) disappeared when LGA was considered without any other complication (Table 3). No association between 
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H.pylori seropositivity and abnormal fetal growth (SGA, FGR and LGA cases) was observed when data were adjusted 
for confounding factors (data not shown). 
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DISCUSSION 
Our findings indicate that H.pylori maternal seropositivity in the first half of pregnancy is associated with the 
development of gestational diabetes mellitus (GDM). 
The prevalence of H.pylori seropositivity in our study population (28.5%) is in line with epidemiologic observations 
where the authors report a prevalence of 20-30% in middle-aged adults in developed countries (Malaty, 2007). 
To the best of our knowledge, this is the first time that a relationship between H.pylori seropositivity and GDM 
development has been demonstrated, while there are several reports that discuss the association between this infection 
and diabetes mellitus. Some studies have shown a higher prevalence of H.pylori infection in people with type 1 (de Luis 
et al., 1998; El-Eshmawy et al., 2011) and type 2 diabetes (Bener et al., 2007; Devrajani et al., 2010). This relationship 
seems to be correlated with gender (Hamed et al., 2008), BMI (Bener et al., 2007; Perdichizzi et al., 1996), the duration 
of diabetes (de Luis et al., 1998), the presence of dyspepsia, cardiovascular autonomic neuropathy (Gulcelik et al., 
2005) and glycated hemoglobin (Chen and Blaser, 2012; Hsieh et al., 2013), whilst other studies have indicated neutral 
or even negative results (Anastasios et al., 2002; Demir et al., 2008; Gillum, 2004). These contradictory findings might 
well be due to the different study populations. Indeed, negative results were often reported when patients with 
gastrointestinal symptoms had been investigated. A recent meta-analysis of 41 observational studies has reported a 
positive association between H.pylori infection and type 2 diabetes, whilst no difference in the rate of H.pylori infection 
was demonstrated between type 1 diabetes patients and the non-diabetic control group (Zhou et al., 2013). 
The interpretation of the association between diabetes mellitus and H.pylori infection is also controversial. On the one 
hand, some authors report that diabetic patients seem to be more prone to acquire H.pylori infection since diabetes 
mellitus induces impairment of cellular and humoral immunity, enhancing sensitivity to infections (Koh et al., 2012). 
Others report that diabetes induces a reduction in gastrointestinal motility and acid secretion, thus promoting pathogen 
colonization and infection rate in the gut (De Block et al., 2006). Perdichizzi et al. state that altered glucose metabolism 
may produce chemical changes in the gastric mucosa that promote H.pylori colonization (Perdichizzi et al., 1996). On 
the other hand, it has been stated that H.pylori positivity could be a risk factor for diabetes development, since H.pylori 
infection increases pro-inflammatory cytokine secretion and reactive oxygen species and leads to changes in the 
structure of the insulin receptor substrate interfering with the interaction with its receptors and inhibiting insulin activity 
(Aslan et al., 2006; Evans et al., 2002; Marette, 2002). It has also been reported that H.pylori infection plays a role in 
the regulation of leptin and ghrelin (Francois et al., 2011), two hormones involved in energy homeostasis where their 
interaction affects obesity, insulin sensitivity and glucose homeostasis (Sun et al., 2006; Williams and Mobarhan, 
11 
 
2003). Furthermore, H.pylori eradication seems to have beneficial effects on insulin resistance, lipid abnormalities and 
low-grade inflammation (Gen et al., 2010). 
Our findings seem to support the second hypothesis, as, in our study, serum antibodies against H.pylori were detected 
before GDM development and it is likely that H.pylori infection occurred before pregnancy. Indeed, H.pylori is usually 
acquired during childhood (Malaty, 2007). Jeon and colleagues also observed the presence of anti-H.pylori antibodies 
before diabetes onset in an elderly population (Jeon et al., 2012). Therefore, it is likely that H.pylori positivity 
predisposes pregnant women for GDM development and the general population for type 2 diabetes mellitus. 
We observed that there was a higher percentage of H.pylori seropositive women with miscarriages (40.5%) 
than in the rest of our population (28.3%), without reaching statistical significance. However, we previously reported 
that if we considered only primigravidae, the difference became significant (Cardaropoli et al., 2013). These findings 
suggest a relationship between H.pylori infection and implantation/placentation failure, possibly due to a cross-reaction 
between antibodies against H.pylori and placental tissue (Franceschi et al., 2012). 
Unfortunately, we could not confirm the relationship between H.pylori infection and pre-eclampsia (PE) 
previously reported by us (Cardaropoli et al., 2011; Ponzetto et al., 2006). This is most likely due to the small number 
of mothers who developed PE (2%), despite the large number of women recruited before 20 weeks of gestation. 
Furthermore, our PE group was particularly heterogeneous and did not mirror the previous study groups. Indeed, the PE 
subjects in our previous case-control studies were mainly mothers with a severe/early-onset pre-eclampsia with no other 
pregnancy-complications (Cardaropoli et al., 2011). In the present investigation there were only 15 (26%) pregnant 
women with the same characteristics and, in this relatively small subgroup, 7 (46.7%) mothers were H.pylori 
seropositive. However, there may be a second explanation for these conflicting results i.e. H.pylori infection might 
occur during pregnancy shortly before the onset of PE symptoms, therefore there is no seropositivity before 20 weeks. 
The study carried out by Lanciers and colleagues (1999) support this hypothesis reporting a significantly increased 
incidence of pregnant subjects with high H.pylori IgM (marker for recently acquired infection) than that observed in 
non pregnant women. Indeed, these authors suggested that pregnancy itself may increase the susceptibility to H.pylori 
infection (Lanciers et al., 1999). We did not demonstrate any relationship between H.pylori infection and obstetric 
cholestasis, spontaneous preterm delivery, pregnancy-related hypertension or fetal growth disorders. 
This prospective cohort study faces a pre-eminent problem of modern obstetrics, since GDM increases the risk 
of complications for both mother and child not only during pregnancy and childbirth but also later in life. In fact, 
besides the changes in glucose homeostasis, pregnant women with previous GDM are more prone to hypertension, 
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hyperlipidemia, cardiovascular alterations and mortality. Furthermore, GDM exposes infants to hyperglycaemia whilst 
in utero and it has been reported that this exposure may have a long-term negative impact on the cardiovascular health 
of the offspring (Marco et al., 2012). 
In conclusion, our data demonstrated for the first time that there is an independent association between the presence of 
antibodies against H.pylori antigens in maternal serum and the development of gestational diabetes mellitus. 
This is a further confirmation that H.pylori infection can have an adverse effect on pregnancy. Therefore, if H.pylori 
infection were to be confirmed as an important risk factor for pregnancy complications, we are of the opinion that pre-
pregnancy diagnosis and preventive H.pylori eradication would be able to help reduce the incidence of some of these 
complications. Further studies are ongoing to provide more information on the possible role of screening for H.pylori 
infection in preventing GDM and other serious pregnancy disorders. 
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HIGHLIGHTS 
• H.pylori seropositivity before 20 wks is associated with gestational diabetes. 
• Maternal H.pylori seropositivity is independently associated with GDM development. 
• H.pylori eradication should prevent diabetes mellitus. 
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Table 1. The characteristics of all recruited cases. 
Characteristic Mean (SD) 
At recruitment  
Maternal age (years) 32.2 (4.5) 
Gestational age (weeks) 13.3 (2.4) 
At delivery  
Gestational weight gain (Kg) 13.0 (4.6) 
Rate of weight gain (Kg/week) 0.34 (0.12) 
Gestational age (weeks) 38.6 (3.2) 
Neonatal birth weight (g) 3,239 (486) 
Neonatal birth weight centile 47.6 (27.8) 
 N (%) 
Continent origin  
European 2,693 (95.5) 
Non european 127 (4.5) 
Pre-pregnancy Body Mass Index  
Underweight (BMI < 18,5) 230 (8.2) 
Normal (18,5 ≤ BMI < 25) 2,009 (71.3) 
Overweight (25 ≤ BMI < 30) 435 (15.4) 
Obese (BMI ≥ 30) 145 (5.1) 
Nulliparous 1,689 (59.9) 
Smoking mothers 321 (11.4) 
Pre-pregnancy pathologies  
Chronic hypertension 51 (1.8) 
Diabetes mellitus 16 (0.6) 
Nephropathy 20 (0.7) 
Thrombophilia 62 (2.2) 
Autoimmune diseases 66 (2.3) 
H.pylori seropositivity 804 (28.5) 
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Table 2. Univariable logistic regression analysis on the association between the presence of H.pylori antibodies in 
maternal serum and major pregnancy-related complications. 
 Total Seropositive   
Outcome N (%) N (%) P value OR (95% CI) 
All GDM cases 160 (5.7) 66 (41.3) 
<0.001 1.829 (1.320 – 2.533) 
Pregnancies without GDM 2,660 (94.3) 738 (27.7) 
All spontaneous preterm deliveries 100 (3.5) 36 (36.0) 
0.093 1.430 (0.942 – 2.169) 
No spontaneous preterm delivery 2,720 (96.5) 768 (28.2) 
All PIH cases 140 (5.0) 35 (25.0) 
0.346 0.828 (0.560 – 1.225) 
Pregnancies without PIH 2,680 (95.0) 769 (28.7) 
All PE cases 57 (2.0) 16 (28.1) 
0.941 0.978 (0.546 – 1.753) 
Pregnancies without PE 2,763 (98.0) 788 (28.5) 
All miscarriage cases 37 (1.3) 15 (40.5) 
0.107 1.723 (0.889 – 3.339) 
Pregnancies without miscarriage 2,783 (98.7) 789 (28.3) 
All Cholestasis cases 34 (1.2) 8 (23.5) 
0.519 0.769 (0.347 – 1.706) 
Pregnancies without Cholestasis 2,786 (98.8) 796 (28.6) 
All SGA cases 133 (4.7) 27 (20.3) 
0.033 0.626 (0.407 – 0.963) 
Pregnancies with no SGA neonates 2,687 (95.3) 777 (28.9) 
All FGR cases 131 (4.6) 45 (34.4) 
0.131 1.331 (0.919 – 1.927) 
Pregnancies with no FGR neonates 2,689 (95.4) 759 (28.2) 
All LGA cases 231 (8.2) 81 (35.1) 
0.022 1.394 (1.050 – 1.851) 
Pregnancies with no LGA neonates 2,589 (91.8) 723 (27.9) 
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Table 3. Univariable logistic regression analysis on the association between the presence of H.pylori antibodies in 
maternal serum and major pregnancy-related disorders without any other maternal complications. 
 Total Seropositive   
Outcome N (%) N (%) P value OR (95% CI) 
GDM 136 (4.8) 58 (42.6) <0.001 1.932 (1.361 – 2.742) 
Spontaneous preterm 75 (2.7) 23 (30.7) 0.675 1.112 (0.676 – 1.830) 
PIH 124 (4.4) 30 (24.2) 0.277 0.793 (0.521 – 1.205) 
PE 48 (1.7) 13 (27.1) 0.825 0.930 (0.490 – 1.768) 
Cholestasis 27 (1.0) 4 (14.8) 0.124 0.433 (0.149 – 1.257) 
SGA 107 (3.8) 21 (19.6) 0.040 0.602 (0.371 – 0.977) 
FGR 103 (3.7) 34 (33.0) 0.304 1.246 (0.819 – 1.895) 
LGA 182 (6.5) 62 (34.1) 0.087 1.320 (0.961 – 1.815) 
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Table 4. Multivariable logistic regression analysis on the association between the presence of H.pylori antibodies in 
maternal serum and major pregnancy-related complications. 
 
GDMa GDM onlyb 
Independent variable p value OR (95% CI) p value OR (95% CI) 
H.pylori seropositivity 0.010 1.599 (1.121-2.280) 0.009 1.655 (1.133-2.416) 
Maternal age <0.001 1.138 (1.091-1.186) <0.001 1.143 (1.093-1.195) 
Body mass index <0.001 1.113 (1.074-1.152) <0.001 1.089 (1.047-1.132) 
Non European 0.035 2.055 (1.053-4.010) 0.008 2.486 (1.269-4.872) 
Cigarette smoking 0.479 1.206 (0.718-2.026) 0.696 1.121 (0.633-1.984) 
Family history for diabetes 0.028 1.572 (1.051-2.354) 0.149 1.387 (0.889-2.163) 
Family history for hypertension 0.263 0.820 (0.580-1.161) 0.291 0.818 (0.564-1.187) 
Chronic hypertension 0.828 0.890 (0.311-2.547) 0.973 0.981 (0.315-3.053) 
Autoimmune disease 0.235 1.723 (0.702-4.231) 0.609 1.319 (0.456-3.814) 
Nephropathy 0.998 0.000 (0.000-∞) 0.998 0.000 (0.000-∞) 
Parity     
Nulliparous <0.001 1 <0.001 1 
Parous w/o previous GDM 0.012 1.601 (1.107-2.316) 0.099 1.391 (0.940-2.058) 
Parous with previous GDM <0.001 13.250 (6.031-29.109) <0.001 11.641 (5.248-25.821) 
a
 with or without any other maternal complication; b without any other maternal complication 
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Supplementary Table 1. Comparison between H.pylori seronegative and seropositive GDM. 
 GDM 
 Seronegative Seropositive 
 (n.94) (n.66) 
 Mean (SD) Mean (SD) 
Maternal age (years) 35.0a (3.9) 33.2 (4.9) 
Gestational age at recruitment (weeks) 13.0 (2.4) 13.3 (3.3) 
Pre-pregnancy BMI (Kg/m2) 23.9b (4.7) 26.4 (6.3) 
Gestational age at delivery (weeks) 38.5 (1.4) 38.6 (1.5) 
Gestational weight gain (Kg) 10.5 (5.1) 10.8 (5.0) 
Neonatal birth weight (g) 3,219 (507) 3,327 (481) 
Neonatal birth weight centile 49.1 (28.3) 56.5 (29.2) 
 N (%) N (%) 
Continent origin   
European 90 (95.7) 58 (87.9) 
Non european 4 (4.3) 8 (12.1) 
Smoking mothers 14 (14.9) 5 (7.6) 
Parity   
Nulliparous 51 (54.3) 37 (56.1) 
Parous w/o previous GDM 34 (36.2) 21 (31.8) 
Parous with previous GDM 9 (9.6) 8 (12.1) 
Chronic hypertension 1 (1.1) 4 (6.1) 
Autoimmune disease 7 (7.4) 8 (12.1) 
Therapy   
Diet 85 (90.4) 60 (90.9) 
Insulin 9 (9.6) 6 (9.1) 
Other complications   
Without other complications 78 (83.0) 58 (87.9) 
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With other complications 16 (17.0) 8 (12.1) 
with Pregnancy-induced hypertension 9 (9.6) 4 (6.1) 
with Pre-eclampsia 6 (6.4) 2 (3.0) 
with Obstetric cholestasis 1 (1.1) 2 (3.0) 
Neonatal birth weight   
AGA 78 (83.0) 52 (78.8) 
SGA 4 (4.3) 2 (3.0) 
FGR 2 (2.1) 2 (3.0) 
LGA 10 (10.6) 10 (15.2) 
aP value from Student’s t-test = 0.013; bP value from Chi-square test = 0.004 
 
 
